Department Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Cannabis Cannabinoid Res. 2022 Oct;7(5):582-590. doi: 10.1089/can.2022.0018. Epub 2022 May 5.
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory distress syndrome coronavirus 2 (SARS-Cov-2), was identified for the first time in late 2019 in China, resulting in a global pandemic of massive impact. Despite a fast development and implementation of vaccination strategies, and the scouting of several pharmacological treatments, alternative effective treatments are still needed. In this regard, cannabinoids represent a promising approach because they have been proven to exhibit several immunomodulatory, anti-inflammatory, and antiviral properties in COVID-19 disease models and related pathological conditions. This mini-review aims at providing a practical brief overview of the potential applications of cannabinoids so far identified for the treatment and prevention of COVID-19, finally considering key aspects related to their technological and clinical implementation.
2019 年冠状病毒病(COVID-19)由严重急性呼吸系统综合征冠状病毒 2(SARS-Cov-2)引起,于 2019 年底在中国首次被发现,导致了全球大规模影响的大流行。尽管疫苗接种策略的快速发展和实施,以及几种药物治疗的探索,仍然需要其他有效的治疗方法。在这方面,大麻素代表了一种有前途的方法,因为它们已被证明在 COVID-19 疾病模型和相关病理条件下具有多种免疫调节、抗炎和抗病毒特性。这篇迷你综述旨在提供迄今为止大麻素在治疗和预防 COVID-19 方面的潜在应用的实用简要概述,最后考虑与它们的技术和临床实施相关的关键方面。